Craig Hallum Begins Coverage on DiaMedica Therapeutics (NASDAQ:DMAC)

Craig Hallum assumed coverage on shares of DiaMedica Therapeutics (NASDAQ:DMAC) in a report released on Wednesday, Marketbeat reports. The firm issued a buy rating and a $8.00 price objective on the stock.

Separately, Oppenheimer restated an outperform rating and issued a $6.00 price target (down previously from $7.00) on shares of DiaMedica Therapeutics in a research note on Thursday, March 21st.

DiaMedica Therapeutics Trading Up 2.0 %

Shares of NASDAQ:DMAC opened at $2.58 on Wednesday. The stock has a fifty day simple moving average of $2.79 and a two-hundred day simple moving average of $2.69. DiaMedica Therapeutics has a 12-month low of $1.53 and a 12-month high of $4.75.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its quarterly earnings data on Wednesday, March 20th. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.14). Research analysts predict that DiaMedica Therapeutics will post -0.69 earnings per share for the current fiscal year.

Institutional Trading of DiaMedica Therapeutics

Large investors have recently modified their holdings of the company. Stonebridge Capital Advisors LLC bought a new stake in shares of DiaMedica Therapeutics in the third quarter worth $52,000. Paragon Associates & Paragon Associates II Joint Venture grew its holdings in shares of DiaMedica Therapeutics by 6.4% in the fourth quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 500,000 shares of the company’s stock worth $1,420,000 after acquiring an additional 30,000 shares during the period. Finally, Avantax Advisory Services Inc. bought a new stake in shares of DiaMedica Therapeutics in the fourth quarter worth $36,000. Institutional investors own 10.12% of the company’s stock.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.